Last reviewed · How we verify
Drug treatment with Cymbalta
Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.
Cymbalta, also known as duloxetine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used to treat depression and anxiety disorders. It is also prescribed for chronic pain conditions such as diabetic neuropathy and fibromyalgia. Despite its effectiveness, Cymbalta has several side effects, including nausea, dizziness, and fatigue. The drug is not approved by the FDA for use at Jefferson Clinic, P.C., which may affect its prescription practices. Patients should be monitored closely for potential adverse reactions and interactions with other medications.
At a glance
| Generic name | Drug treatment with Cymbalta |
|---|---|
| Also known as | Duloxetine Hydrochloride |
| Sponsor | Jefferson Clinic, P.C. |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin and norepinephrine transporters |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Cymbalta works by blocking the reabsorption (reuptake) of serotonin and norepinephrine into neurons, thereby increasing their availability in the synaptic cleft.
Approved indications
Boxed warnings
- Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults
Common side effects
- Nausea
- Dizziness
- Fatigue
- Dry mouth
- Constipation
- Somnolence
- Decreased appetite
- Sweating
- Headache
Drug interactions
- Monoamine oxidase inhibitors (MAOIs)
- Serotonergic drugs (e.g., SSRIs, triptans)
- Drugs that affect serotonin or norepinephrine metabolism
Key clinical trials
- Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (PHASE2)
- Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM) (NA)
- Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA) (NA)
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US6127396 | ||
| US6326381 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug treatment with Cymbalta CI brief — competitive landscape report
- Drug treatment with Cymbalta updates RSS · CI watch RSS
- Jefferson Clinic, P.C. portfolio CI